Veralox Therapeutics is a technology company.
Veralox Therapeutics has raised $46.0M across 3 funding rounds.
Veralox Therapeutics has raised $46.0M in total across 3 funding rounds.
Veralox Therapeutics has raised $46.0M in total across 3 funding rounds.
Veralox Therapeutics's investors include Hatteras Venture Partners, T1D Fund.
Veralox Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule therapeutics targeting underlying pathologies of immune-mediated and inflammatory diseases, particularly heparin-induced thrombocytopenia and thrombosis (HIT/T), type 1 diabetes (T1D), and related rare blood disorders.[1][2][3] Its lead candidate, VLX-1005, a selective 12-LOX inhibitor, addresses unmet needs in HIT/T patients and received FDA Fast Track designation after favorable Phase 1 results in 2022; the company serves patients with these conditions through innovative drug discovery accelerated by expert founders.[1][2][4] With $16.6M in total funding, Veralox demonstrates growth momentum as a private firm backed by investors like Pappas Capital and Genesys Capital, focusing on thrombosis and immuno-inflammatory therapies impacting hundreds of thousands annually.[2][3][5]
Veralox Therapeutics, LLC launched in 2017 (with some sources noting 2018) in Frederick, Maryland, founded by drug discovery and development experts from Avalon, Human Genome Sciences, and NIH/NCATS, bringing proven commercialization success.[1][2] The idea emerged from their deep expertise in small molecule innovation to tackle unmet needs in immune-mediated diseases, leading to the rapid development of VLX-1005 for HIT/T—a condition with limited treatments—and expansion to T1D and other inflammatory disorders.[1][2][3] Early traction included securing $16.6M in funding, advancing to clinical stage, and achieving positive Phase 1 data by 2022, marking pivotal milestones under CEO Jonathan Mow.[2][4]
Veralox rides the wave of precision medicine in immunology and hematology, targeting rare but devastating diseases like HIT/T amid rising demand for small molecule therapies in immune-inflammatory spaces.[1][2][6] Timing aligns with FDA incentives like Fast Track for orphan indications and growing venture interest in biotech post-2020 funding surges, fueled by advances in molecular pathway understanding (e.g., 12-LOX inhibition).[2][4] Market forces favoring Veralox include high unmet needs in thrombosis (hundreds of thousands affected yearly) and T1D, plus biotech hubs like Maryland's ecosystem via Maryland Momentum Fund.[3] It influences the landscape by pioneering selective inhibitors, potentially setting paradigms for immuno-hematologic treatments and attracting follow-on innovation in rare disease drug development.[1][5][7]
Veralox is poised for Phase 2/3 trials of VLX-1005, leveraging Fast Track momentum toward potential approvals in HIT/T, with pipeline expansion into T1D signaling broader immuno-inflammatory ambitions.[2][4] Trends like AI-driven drug discovery and orphan drug incentives will shape its path, amplifying efficiency in small molecule development amid biotech M&A waves. Its influence may grow through partnerships or acquisition by big pharma seeking rare disease assets, solidifying its role as a Frederick biotech leader—echoing its founding mission to accelerate first-in-class therapies for the underserved.[1][5]
Veralox Therapeutics has raised $46.0M across 3 funding rounds. Most recently, it raised $24.0M Venture Round in June 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2023 | $24.0M Venture Round | Hatteras Venture Partners, T1D Fund | |
| Jun 1, 2021 | $17.0M Series A | Hatteras Venture Partners, T1D Fund | |
| Sep 1, 2019 | $5.0M Seed | Hatteras Venture Partners, T1D Fund |